Randox Laboratories has released a number of products for the testing of legal and illegal drugs in laboratories, incorporating homogenous methodology, Biochip Array Technology and Quality Management.
According to Randox, high demand for forensic investigations has put toxicologists under pressure to produce case evidence without delay.
Such evidence is vital to understanding events such as road accidents, poisoning and other causes of death.
Testing of biological samples can be used to determine the presence of legal and illegal substances which may have been an influencing factor.
In 2010 Randox released a Drugs of Abuse array (DoA I+), adding to its test menu of legal and illegal drugs.
Tests available include; amphetamine, methamphetamine, barbituates, benzodiazepine 1 and 2, cannabinoids, cocaine metabolite, methadone, opiates and phencyclidine, buprenorphine, fentanyl, generic opioids, ketamine, LSD, MDMA, methaqualone, oxycodone 1 and 2, propoxyphene, MDMA, Buprenorphine and TCA.
All tests are measured simultaneously from a single sample.
A number of drugs analytes are grouped and carried out on a biochip to allow for consolidated testing.
Randox state that Biochip Array Technology has been an important development in the practice of forensic analysis, creating a reduction in the amount of time spent on individual tests.
The multi-marker process allows toxicologists to determine a substantial amount of information from a small volume of sample, where sample is often limited.
Most importantly, the technology incorporates proven ELISA principles and provides accurate and reliable results which can be relied on in court.
Forensic evidence may be used in court, therefore it is crucial to have quality-assured products and procedures in place.
Randox manufacture antibodies onsite allowing them to sustain quality while continually expanding their test portfolio.
The company also offers drug-testing solutions for clinical toxicology, workplace drug testing and onsite testing environments.